CTLA4 and metastatic melanoma: In patients with metastatic melanoma resistant to anti-PD-L1 monotherapy, combination of anti-CTLA4 plus anti-PD-1 resulted in a median 3·0 months progression-free survival (PFS) compared to anti-CTLA4 alone with 2·6 months PFS [36].